DOCSLIB.ORG

On the Mechanism of Action of the Non-Opioid Analgesic Flupirtine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
On the Mechanism of Action of the Non-Opioid Analgesic Flupirtine ON THE MECHANISM OF ACTION OF THE NON-OPIOID ANALGESIC FLUPIRTINE Doctoral Thesis at the Medical University of Vienna for obtaining the academic degree Doctor of Philosophy (PhD) Submitted by Felicia Klinger, MD Supervised by Prof. Dr. Stefan Böhm Center for Physiology and Pharmacology Department of Neurophysiology and Pharmacology Waehringerstr. 13a, 1090 Vienna Vienna, 12/2011 1. LIST OF ABBREVIATIONS...........................................................................................3 2. ABSTRACT .......................................................................................................................5 3. ZUSAMMENFASSUNG...................................................................................................6 4. INTRODUCTION .............................................................................................................8 4.1 Pain and nociception ..................................................................................................8 4.2 Nociceptive system ....................................................................................................8 4.3 Pain perception.........................................................................................................10 4.4 Pain sensitisation......................................................................................................12 4.5 Pain transmission .....................................................................................................15 4.6 Pain modulation .......................................................................................................18 4.7 Analgesics................................................................................................................20 4.8 Flupirtine..................................................................................................................24 4.9 Aims of the study .....................................................................................................27 5. MATERIALS AND METHODS....................................................................................28 5.1 Tissue preparation and cell culture ..........................................................................28 5.1.1 Hippocampal and dorsal horn cell cultures.............................................28 5.1.2 Superior cervical ganglia and dorsal root ganglia cell cultures.............29 5.1.3 Cell line and transfection...........................................................................30 5.2 Electrophysiological recordings...............................................................................30 5.2.1 General considerations ..............................................................................30 5.2.2 Patch clamp set up .....................................................................................31 5.2.3 Recording and analysis of autaptic currents ...........................................33 5.2.4 Recording currents through ligand-gated ion channels .........................33 5.2.5 Recording of miniature inhibitory postsynaptic currents (mIPSCs) ....34 5.2.6 Recording currents through KCNQ/Kv7 channels (IM).........................34 5.2.7 Calculations and statistics .........................................................................35 5.3 Western blot analysis ...............................................................................................35 5.3.1 Principle of Western blot analysis ............................................................35 5.3.2 Membrane protein preparation................................................................36 5.3.3 Preparation of the polyacrylamide gels and electrophoresis .................36 5.3.4 Blotting and immunostaining....................................................................37 5.4 Materials...................................................................................................................38 6. RESULTS.........................................................................................................................40 6.1 Flupirtine enhances currents through Kv7 channels................................................40 1 6.2 Flupirtine enhances inhibitory, but not excitatory, autaptic currents in hippocampal microculture........................................................................................41 6.3 GABAA receptors, but no other ligand-gated ion channels are modulated by low micromolar flupirtine concentrations.......................................................................42 6.4 Flupirtine acts as an allosteric modulator on GABAA receptors in hippocampal neurons.....................................................................................................................44 6.5 Flupirtine enhances currents through tonically-active GABAA receptors but does not alter synaptic transmission.................................................................................46 6.6 When synaptic GABAA receptors are blocked by Penicillin G 5 mM, flupirtine acts as a pure potentiator on GABAA receptors in hippocampal neurons................50 6.7 Effects of flupirtine on GABAA receptors in pain-related and non-related neurons.....................................................................................................................51 6.8 Differences in GABAA receptor subunits in pain-related and non-related neurons 53 6.9 Effects of flupirtine on Kv7 channels in pain-related and non-related neurons ......55 6.10 Concentration dependence of the effects of flupirtine on GABAA receptors in pain-related and non-related neurons; comparison with the effects on Kv7............56 7. DISCUSSION...................................................................................................................58 8. REFERENCES ................................................................................................................63 9. ACKNOWLEDGMENTS...............................................................................................81 10. CURRICULUM VITAE .................................................................................................82 2 1. LIST OF ABBREVIATIONS 5-HT ………………………………………………………..5-hydroxtryptamine (serotonin) aEPSC ………………………………………….…autaptic excitatory postsynaptic currents aIPSC ……………………………………………..autaptic inhibitory postsynaptic currents AIS ………………………………………………….………………..axonal initial segment AMPA …………………………...α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid APS ………………………………………….………………………..ammonium persulfate ATP …………………………………………….…………………....adenosine triphosphate BCA …………………………………………...…………………………bicinchoninic acid Bis-tris ……………………...……..Bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methan BMI ………………………………………………………………….bicuculline methionide cAMP ……………………………………………………..cyclic adenosine monophosphate 2+ CaV channels .…………………………………………..………voltage-gated Ca channels CNQX ……………………………………...……..cyano-2,3-dihydroxy-7-nitroquinoxaline CNS ………………………………………………………………….central nervous system COX ...………………………………………………………………………cyclooxygenase DAD ……………………………………………...………………………….diacyl glycerol DH …………………………………………………...…………………………..dorsal horn DMEM ………………………………………………Dulbecco’s modified Eagle’s medium DRG ……………………………………………………………………...dorsal root ganglia EDTA ………………………………………………………ethylenediaminetetraacetic acid EPSC ……………………………………………………......excitatory postsynaptic current FCS ……………………………………………………………...…………..fetal calf serum GABA ……………………………………………………………gamma amino butiric acid GIRK channels ………………………...G-protein coupled inwardly rectifying K+ channels GPCR ……………………………………………………………G protein coupled receptor HB ……………………………………………………………………..homogenizing buffer HEK cells ………………………………………………...…human embryonic kidney cells HEPES ………………………………..4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid hiFCS ………………………………………………………heat inactivated fetal calf serum IPSP …………………………………………………...…..inhibitory postsynaptic potential IM …………………………………………………. M-current (current through M-channel) 3 IP3 ………………………………………………………...……..inositol 1,4,5-triphosphate mIPSC …………………………………………..miniature inhibitory postsynaptic currents mEPSC ……………………………………….....miniature excitatory postsynaptic currents MOPS ………………………………………………3-(N-morpholino)propanesulfonic acid mRNA ………………………………………………...………...messenger ribonucleic acid + NaV channels …………………………………………………...voltage-gated Na channels NBQX ..................2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide NGF ……………………………………………………………...….neuronal growth factor NKA …………………………………………………………………...………neurokinin A NMDA ..................................................................................................N-methyl-D-aspartate NO …………………………………………………………………………...…..nitric oxide NSAIDs …..................................................................non-steroidal anti-inflammatory drugs PBS ……………………………………………………………….phosphate buffered saline PCR …………………………………………………………...…polymerase chain reaction PLC ……………………………………………………………………...…phospholipase C PGE ……………………………………………………………………...….prostaglandin E PIP2 ……………………………………………….....phosphatidylinositol 4,5-bisphosphate PKC ………………………………………………………………...………protein kinase C PNS ………………………………………………………………peripheral nervous system PVDF .................................................................................................polyvinylidene fluoride rpm ……………………………………………………………………..rotations per minute SCG ………………………………………………………………..superior cervical ganglia SDS ..................................................................................................sodium
Load more

Recommended publications
  • Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls
    toxins Review Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls 1 2 3, 4, , Marie-Line Reynaert , Denis Dupoiron , Edouard Yeramian y, Laurent Marsollier * y and 1, , Priscille Brodin * y 1 France Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France 2 Institut de Cancérologie de l’Ouest Paul Papin, 15 rue André Boquel-49055 Angers, France 3 Unité de Microbiologie Structurale, Institut Pasteur, CNRS, Univ. Paris, F-75015 Paris, France 4 Equipe ATIP AVENIR, CRCINA, INSERM, Univ. Nantes, Univ. Angers, 4 rue Larrey, F-49933 Angers, France * Correspondence: [email protected] (L.M.); [email protected] (P.B.) These three authors contribute equally to this work. y Received: 29 June 2019; Accepted: 3 September 2019; Published: 4 September 2019 Abstract: Pain currently represents the most common symptom for which medical attention is sought by patients. The available treatments have limited effectiveness and significant side-effects. In addition, most often, the duration of analgesia is short. Today, the handling of pain remains a major challenge. One promising alternative for the discovery of novel potent analgesics is to take inspiration from Mother Nature; in this context, the detailed investigation of the intriguing analgesia implemented in Buruli ulcer, an infectious disease caused by the bacterium Mycobacterium ulcerans and characterized by painless ulcerative lesions, seems particularly promising. More precisely, in this disease, the painless skin ulcers are caused by mycolactone, a polyketide lactone exotoxin. In fact, mycolactone exerts a wide range of effects on the host, besides being responsible for analgesia, as it has been shown notably to modulate the immune response or to provoke apoptosis.
    [Show full text]
  • Ketamine: an Update for Its Use in Complex Regional Pain Syndrome
    xperim & E en l ta a l ic P in h Bentley et al., Clin Exp Pharmacol 2015, 5:2 l a C r m f Journal of DOI: 10.4172/2161-1459.1000169 o a l c a o n l o r g u y o J ISSN: 2161-1459 Clinical and Experimental Pharmacology Commentry Open Access Ketamine: An Update for Its Use in Complex Regional Pain Syndrome and Major Depressive Disorder William E Bentley*, Michael Sabia, Michael E Goldberg and Irving W Wainer Cooper University Hospital, Camden, New Jersey, United States of America Abstract In recent years, there has been significant research in regard to the efficacy of ketamine in regards to treating Complex Regional Pain Syndrome (CRPS) and Major Depressive Disorder (MDD). Many patients have had substantial symptomatic relief; however, not all patients have had positive results. This has prompted current research with evidence to suggest certain biomarkers exist that would infer which patients will/will not respond to ketamine treatment. Current biomarkers of interest include D-Serine (D-Ser) and magnesium, which will be discussed. Whether or not D-Ser and/or magnesium levels should be checked and possibly dictate therapy is an area of future research. It is also possible that downstream metabolites of ketamine are the key to successful therapy. Keywords: Complex regional pain syndrome; Major Depressive thoughts; and slowing of speech and action. These changes must last a Disorder(MDD); Ketamine minimum of 2 weeks and interfere considerably with work and family relations” [6]. Treatment options include antidepressant medications, Complex Regional Pain Syndrome (CRPS) and Major Depressive cognitive behavioral therapy, and interpersonal therapy.
    [Show full text]
  • ACPA Guide to Pain Management
    [Document title] [Document subtitle] Abstract [Draw your reader in with an engaging abstract. It is typically a short summary of the document. When you’re ready to add your content, just click here and start typing.] ACPA [Email address] 1 ACPA Resource Guide To Chronic Pain Management An Integrated Guide to Medical, Interventional, Behavioral, Pharmacologic and Rehabilitation Therapies 2019 Edition American Chronic Pain Association P.O. Box 850 Rocklin, CA 95677 Tel 800-533-3231 Fax 916-652-8190 E-mail [email protected] Web Site http://www.theacpa.org Copyright 2019 American Chronic Pain Association, Inc. All rights reserved. No portion of this book may be reproduced without permission of the American Chronic Pain Association, Inc. 2 Table of Contents A STATEMENT FROM THE ACPA BOARD OF DIRECTORS ...........................................................................................................................5 INTRODUCTION ........................................................................................................................................................................................................6 OVERVIEW OF CHRONIC PAIN TREATMENT ..................................................................................................................................................8 WHAT DOES SUCCESSFUL PAIN TREATMENT LOOK LIKE? .......................................................................................................................8 PAIN TYPES, SOURCES & CLASSIFICATION .....................................................................................................................................................9
    [Show full text]
  • Membrane Stabilizer Medications in the Treatment of Chronic Neuropathic Pain: a Comprehensive Review
    Current Pain and Headache Reports (2019) 23: 37 https://doi.org/10.1007/s11916-019-0774-0 OTHER PAIN (A KAYE AND N VADIVELU, SECTION EDITORS) Membrane Stabilizer Medications in the Treatment of Chronic Neuropathic Pain: a Comprehensive Review Omar Viswanath1,2,3 & Ivan Urits4 & Mark R. Jones4 & Jacqueline M. Peck5 & Justin Kochanski6 & Morgan Hasegawa6 & Best Anyama7 & Alan D. Kaye7 Published online: 1 May 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review Neuropathic pain is often debilitating, severely limiting the daily lives of patients who are affected. Typically, neuropathic pain is difficult to manage and, as a result, leads to progression into a chronic condition that is, in many instances, refractory to medical management. Recent Findings Gabapentinoids, belonging to the calcium channel blocking class of drugs, have shown good efficacy in the management of chronic pain and are thus commonly utilized as first-line therapy. Various sodium channel blocking drugs, belonging to the categories of anticonvulsants and local anesthetics, have demonstrated varying degrees of efficacy in the in the treatment of neurogenic pain. Summary Though there is limited medical literature as to efficacy of any one drug, individualized multimodal therapy can provide significant analgesia to patients with chronic neuropathic pain. Keywords Neuropathic pain . Chronic pain . Ion Channel blockers . Anticonvulsants . Membrane stabilizers Introduction Neuropathic pain, which is a result of nervous system injury or lives of patients who are affected. Frequently, it is difficult to dysfunction, is often debilitating, severely limiting the daily manage and as a result leads to the progression of a chronic condition that is, in many instances, refractory to medical This article is part of the Topical Collection on Other Pain management.
    [Show full text]
  • Intrathecal Drug Infusions
    INTRATHECAL DRUG INFUSIONS RATIONAL USE OF POLYANALGESIA TIMOTHY R. DEER, MD • PRESIDENT AND CEO, THE CENTER FOR PAIN RELIEF, CHARLESTON, WEST VIRGINIA • CLINICAL PROFESSOR OF ANESTHESIOLOGY, WEST VIRGINIA UNIVERSITY • BOARD OF DIRECTORS, INTERNATIONAL NEUROMODULATION SOCIETY • IMMEDIATE PAST CHAIR, AMERICAN SOCIETY OF ANESTHESIOLOGISTS, COMMITTEE ON PAIN MEDICINE • BOARD OF DIRECTORS; AMERICAN ACADEMY OF PAIN MEDICINE AND AMERICAN SOCIETY OF INTERVENTIONAL PAIN PHYSICIANS 2 INS 2009 • SYMPOSIUM ON INTRATHECAL DRUG DELIVERY • DISCLOSURES IN INTRATHECAL DRUG DELIVERY • CONSULTANT: INSET, JOHNSON AND JOHNSON. Intrathecal Pump for Pain ! 1 mg intrathecal morphine = 300 mg oral morphine CONFIDENTIAL Krames ES. J Pain Symptom Manage. 1996 Jun;11(6):333-52 4 Objectives • Review current options for pump infusions • Build on the talks of Dr. Levy and Dr. Abejon • Use a case based approach to discuss the issues • Make conclusions regarding the algorithm of Intrathecal analgesia Clinical Decision Making • Regulatory Approval in your country • Case reports • Lectures and anecdotal information • Retrospective analysis • Double-blind, randomized, prospective studies • Physician innovation with no available evidence • Consensus Statements 2000 Guidelines for Intraspinal Infusion 2007 Polyanalgesic Consensus Guidelines for Management of Pain by Intraspinal Drug Delivery Line 1 Morphine or Hydromorphone or Ziconotide Fentanyl or Clonodine alone OR one of the following 2-drug Line 2 combinations: • Morphine (or Hydromorphone) + Ziconotide • Morphine (or
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Future Local Anesthetics: Neurotoxins?
    FUTURE PERSPECTIVE Future local anesthetics: Neurotoxins? Prasanna Vadhanan C. MD*, Adhinarayanan S, DA, DNB** *Associate Professor, Department of Anesthesiology, Vinayaka Mission’s Medical College & Hospitals (VMMCH),Karaikal (India) **Associate Professor, Department of Anesthesiology, Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Puducherry (India) Correspondence: Dr. Prasanna Vadhanan, Associate Professor, Department of Anesthesiology, Vinayaka Mission’s Medical College & Hospitals (VMMCH), Karaikal (India) ABSTRACT This review article gives a look into the efforts being made to develop local anesthetics from new molecules, thus offering a better safety profile. Neurotoxins are a varied group of compounds, both chemically and pharmacologically. These encompass a wide group of drugs which acts on various ionic channels like sodium, potassium, calcium and chloride channels. The differences between current agents and the new group are presented. Tetrodotoxin and saxitoxin (STX) are the two more prominent groups of neurotoxins. Their characteristics are outlined. Key words: Local anesthetics; Neurotoxins; Tetrodotoxin; Saxitoxin Citation: Vadhanan P, Adhinarayanan S. Future local anesthetics: Neurotoxins?. Anaesth Pain & Intensive Care 2014;18(3):308-312 INTRODUCTION properties The use of cocaine by Koller in 1884 heralded a new class 1. No or minimal systemic toxicity of drugs which would later prove indispensable in routine 2. Longer shelf life anesthesia practice. Local anesthetic agents are one of the 3. Better sensory motor separation most widely used drugs for providing and or supplementing 4. Prolonged action analgesia . Lignocaine (1943) and bupivacaine (1963), 5. Stability quickly replaced cocaine and procaine because of their 6. No tissue irritation better safety profile. Even with the introduction of newer 7. Easily metabolized local anesthetics like ropivacaine and levobupivacaine, the By the current knowledge of NaV isoforms, it would be search for the ideal local anesthetic is still on.
    [Show full text]
  • Package Leaflet: Information for the User
    ENR 2186544 ENR 2186545 PACKAGE LEAFLET: INFORMATION FOR THE USER <invented name> 100 mg capsules, hard Active substance: flupirtine maleate Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. What is in this leaflet 1. What <invented name> is and what it is used for 2. What you need to know before you take <invented name> 3. How to take <invented name> 4. Possible side effects 5. How to store <invented name> 6. Contents of the pack and other information 1. What <invented name> is and what it is used for <invented name> is a medicine used to treat acute pain of mild to moderate intensity coming from various origins. 2. What you need to know before you take <invented name> Do not take <invented name> - if you are allergic to flupirtine maleate or any of the other ingredients of this medicine (listed in section 6). - if you are at risk of hepatic encephalopathy and patients with cholestasis, <invented name> should not be administered, as onset or deterioration of encephalopathy or ataxia may occur in these patients.
    [Show full text]
  • Conotoxins As Tools to Understand the Physiological Function of Voltage-Gated Calcium (Cav) Channels
    marine drugs Review Conotoxins as Tools to Understand the Physiological Function of Voltage-Gated Calcium (CaV) Channels David Ramírez 1,2, Wendy Gonzalez 1,3, Rafael A. Fissore 4 and Ingrid Carvacho 5,* 1 Centro de Bioinformática y Simulación Molecular, Universidad de Talca, 3460000 Talca, Chile; [email protected] (D.R.); [email protected] (W.G.) 2 Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, 3460000 Talca, Chile 3 Millennium Nucleus of Ion Channels-Associated Diseases (MiNICAD), Universidad de Talca, 3460000 Talca, Chile 4 Department of Veterinary and Animal Sciences, University of Massachusetts, Amherst, MA 01003, USA; rfi[email protected] 5 Department of Biology and Chemistry, Faculty of Basic Sciences, Universidad Católica del Maule, 3480112 Talca, Chile * Correspondence: [email protected]; Tel.: +56-71-220-3518 Received: 8 August 2017; Accepted: 4 October 2017; Published: 13 October 2017 Abstract: Voltage-gated calcium (CaV) channels are widely expressed and are essential for the completion of multiple physiological processes. Close regulation of their activity by specific inhibitors and agonists become fundamental to understand their role in cellular homeostasis as well as in human tissues and organs. CaV channels are divided into two groups depending on the membrane potential required to activate them: High-voltage activated (HVA, CaV1.1–1.4; CaV2.1–2.3) and Low-voltage activated (LVA, CaV3.1–3.3). HVA channels are highly expressed in brain (neurons), heart, and adrenal medulla (chromaffin cells), among others, and are also classified into subtypes which can be distinguished using pharmacological approaches. Cone snails are marine gastropods that capture their prey by injecting venom, “conopeptides”, which cause paralysis in a few seconds.
    [Show full text]
  • Muscle Relaxants for Pain Management in Rheumatoid Arthritis (Review)
    Muscle relaxants for pain management in rheumatoid arthritis (Review) Richards BL, Whittle SL, Buchbinder R This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2012, Issue 1 http://www.thecochranelibrary.com Muscle relaxants for pain management in rheumatoid arthritis (Review) Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 3 BACKGROUND .................................... 6 OBJECTIVES ..................................... 7 METHODS ...................................... 7 RESULTS....................................... 10 Figure1. ..................................... 11 Figure2. ..................................... 13 Figure3. ..................................... 15 Figure4. ..................................... 15 Figure5. ..................................... 16 Figure6. ..................................... 17 Figure7. ..................................... 17 Figure8. ..................................... 18 DISCUSSION ..................................... 20 AUTHORS’CONCLUSIONS . 21 ACKNOWLEDGEMENTS . 22 REFERENCES ..................................... 22 CHARACTERISTICSOFSTUDIES . 24 DATAANDANALYSES. 35 Analysis 1.1. Comparison 1 Muscle relaxant versus control, Outcome 1 Pain 24hrs. 37 Analysis 1.2. Comparison 1 Muscle relaxant
    [Show full text]
  • 022345Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 022345Orig1s000 OTHER REVIEW(S) SEALD LABELING: PI SIGN-OFF REVIEW APPLICATION NUMBER NDA 022345 APPLICANT Valeant Pharm N.A. PRODUCT NAME Potiga (ezogabine) SUBMISSION DATE 15 April 2011 PDUFA DATE 15 June 2011 SEALD SIGN-OFF DATE 10 June 2011 OND ASSOCIATE DIRECTOR Laurie Burke FOR STUDY ENDPOINTS AND LABELING This memo confirms that no critical prescribing information (PI) deficiencies were noted in the SEALD Labeling Review filed 8 June 2011 and no critical deficiencies have been found in the final agreed-upon PI reviewed today. SEALD has no objection to PI approval at this time. Reference ID: 2959126 --------------------------------------------------------------------------------------------------------- This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. --------------------------------------------------------------------------------------------------------- /s/ ---------------------------------------------------- LAURIE B BURKE 06/10/2011 Reference ID: 2959126 NDA 22345 Potiga Potiga PMR/PMC Development Template: PREA Efficacy/Safety Study for Ezogabine PMR # 1 This template should be completed by the PMR/PMC Development Coordinator and included for each PMR/PMC in the Action Package. PMR/PMC Description: Prospective, randomized, placebo-control, double-blinded efficacy/ safety trial of Potiga (ezogabine) in children >12 years old. PMR/PMC Schedule Milestones: Final protocol Submission Date: 11/2012 Study/Clinical trial Completion Date: 01/2018 Final Report Submission Date: 05/2018 Other: MM/DD/YYYY 1. During application review, explain why this issue is appropriate for a PMR/PMC instead of a pre-approval requirement. Check type below and describe. Unmet need Life-threatening condition Long-term data needed Only feasible to conduct post-approval Prior clinical experience indicates safety Small subpopulation affected Theoretical concern Other This is part of a PREA requirement.
    [Show full text]
  • Activation of Axonal Kv7 Channels In
    Fleckenstein et al. Journal of Translational Medicine 2013, 11:34 http://www.translational-medicine.com/content/11/1/34 RESEARCH Open Access Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo - therapeutic potential for peripheral neuropathies: results of a randomised controlled trial Johannes Fleckenstein1*, Ruth Sittl1,2, Beate Averbeck2, Philip M Lang1, Dominik Irnich1 and Richard W Carr2,3 Abstract Background: Flupirtine is an analgesic with muscle-relaxing properties that activates Kv7 potassium channels. Kv7 channels are expressed along myelinated and unmyelinated peripheral axons where their activation is expected to reduce axonal excitability and potentially contribute to flupirtine’s clinical profile. Trial design: To investigate the electrical excitability of peripheral myelinated axons following orally administered flupirtine, in-vitro experiments on isolated peripheral nerve segments were combined with a randomised, double-blind, placebo-controlled, phase I clinical trial (RCT). Methods: Threshold tracking was used to assess the electrical excitability of myelinated axons in isolated segments of human sural nerve in vitro and motoneurones to abductor pollicis brevis (APB) in situ in healthy subjects. In addition, the effect of flupirtine on ectopic action potential generation in myelinated axons was examined using ischemia of the lower arm. Results: Flupirtine (3-30 μM) shortened the relative refractory period and increased post-conditioned superexcitability in human myelinated axons in vitro. Similarly, in healthy subjects the relative refractory period of motoneurones to APB was reduced 2 hours after oral flupirtine but not following placebo. Whether this effect was due to a direct action of flupirtine on peripheral axons or temperature could not be resolved.
    [Show full text]